On June 18, according to market news, the clinical-stage ophthalmic biopharmaceutical company Eyenovia announced it will invest $50 million to launch the Hyperliquid (HYPE) treasury reserve strategy.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Biotech company Eyenovia launches HYPE treasury reserve strategy, investing $50 million.
On June 18, according to market news, the clinical-stage ophthalmic biopharmaceutical company Eyenovia announced it will invest $50 million to launch the Hyperliquid (HYPE) treasury reserve strategy.